Submit Manuscript  

Article Details


In Vitro and In Vivo Antimetastatic Effects of ZSTK474 on Prostate Cancer DU145 Cells

[ Vol. 18 , Issue. ]

Author(s):

Jie Liu, Xiao Tan, Wennan Zhao, Jing Liu, Xiaoxue Xing, Guanwei Fan, Ping Zhang, Zhe Zhang, Yuxu Zhong* and Dexin Kong*Pages 1-9 (9)

Abstract:


Background: Metastasis is the main cause of lethality of prostate cancer. Inhibition of metastasis is expected to be a promising approach for prostate cancer therapy. Phosphatidylinositol 3-kinase (PI3K)/Akt pathway is known to play key roles in cell growth, migration, etc. Objective: Investigate the antimetastatic activities of pan-PI3K inhibitor ZSTK474 on prostate cancer DU145 cells. Methods: 1. In vitro effect of ZSTK474 on the migration, invasion and adhesion of DU145 cells was determined with Transwell migration assay and wound healing assay, Tranwell invasion assay, and adhesion assay, respectively. 2. In vitro effect of ZSTK474 on the signal proteins in DU145 cells was determined with Western blot analysis and ELISA. 3. In vivo antimetastatic effect of ZSTK474 was evaluated with MicroCT and histology analysis. Results: ZSTK474 potently inhibited migration, invasion and adhesion of DU145 cells, negatively regulated Girdin, Integrin1 and matrix metalloproteinases (MMPs). In addition, the expression of hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF), which are known to be related to angiogenesis and metastasis, was also inhibited. Oral administration of ZSTK474 (200 mg/kg) ameliorated in vivo bone metastasis of DU145 cells, with improved bone structure and bone mineral density (BMD). Tissue staining indicated reduction of metastatic DU145 cells and osteoclasts in the bones of ZSTK474-treated mice, compared with the non-treated group. Conclusion: Our result demonstrated the in vitro and in vivo antimetastatic effect of pan-PI3K inhibitor ZSTK474 on prostate cancer DU145 cells, suggesting the potential application in prostate cancer patients.

Keywords:

PI3K inhibitor, ZSTK474, antimetastasis, in vivo, DU145, prostate cancer.

Affiliation:

Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070, State key laboratory of modern Chinese medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, State key laboratory of modern Chinese medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070



Read Full-Text article